Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT-Reference-Cited by-同舟云学术

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT

Published:2017-02-07 Issue:4 Volume:92 Page:344-350
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Canaani Jonathan¹^ORCID,Beohou Eric²³,Labopin Myriam²³,Socié Gerard³,Huynh Anne⁴,Volin Liisa⁵,Cornelissen Jan⁶,Milpied Noel⁷,Gedde-Dahl Tobias⁸,Deconinck Eric⁹,Fegueux Nathalie¹⁰,Blaise Didier¹¹,Mohty Mohamad²,Nagler Arnon¹³

Affiliation:

1. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer; Tel Aviv University; Israel

2. Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Universite Pierre & Marie Curie; Paris France

3. EBMT Acute Leukemia Working Party office, Hôpital Saint-Antoine; Paris France

4. Institut Universitaire du Cancer Toulouse, Oncopole; Toulouse France

5. HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit; Helsinki Finland

6. Department of Hematology; Erasmus MC Cancer Institute, University Medical Center Rotterdam; Rotterdam The Netherlands

7. CHU Bordeaux, Hôpital Haut-leveque; Pessac France

8. Department of Hematology, Clinic for Cancer, Surgery and Transplantation; Oslo University Hospital, Rikshospitalet; Oslo Norway

9. Service d`Hématologie; Hopital Jean Minjoz; Besancon France

10. Département d`Hématologie Clinique; CHU Lapeyronie; Montpellier France

11. Centre de Recherche en Cancérologie de Marseille; Programme de Transplantation & Therapie Cellulaire; Marseille France

Publisher

Wiley

Subject

Hematology

Reference31 articles.

1. Risk factors for acute GVHD and survival after hematopoietic cell transplantation;Jagasia;Blood,2012

2. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials;Gale;Blood,2005

3. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy;Pratcorona;Blood,2013

4. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML;Bornhauser;Blood,2007

5. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML;Meshinchi;Blood,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant expression of Human Endogenous Retrovirus K9-derived elements is associated with better clinical outcome of acute myelocytic leukemia;2024-06-11

2. Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies;International Journal of Molecular Sciences;2024-06-08

3. Treatment outcomes of pediatrics acute myeloid leukemia (AML) and associated factors in the country’s tertiary referral hospital, Ethiopia;BMC Cancer;2024-05-24

4. A transcriptomic based deconvolution framework for assessing differentiation stages and drug responses of AML;npj Precision Oncology;2024-05-18

5. Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations;International Journal of Molecular Sciences;2024-05-07